Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Oxford English Corpus: Facts about the language, The Story of Dictionaries
Sustained cortical and subcortical neuromodulation induced by electrical tongue stimulation.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
The complex role of estrogens in inflammation.
Teriflunomide for multiple sclerosis.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Risk alleles for multiple sclerosis identified by a genomewide study.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Safety Study of Combination Therapy with Intramuscular Avonex and Oral CellCept in Patients with Multiple Sclerosis
Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Pages